Steeped in Science
Total Page:16
File Type:pdf, Size:1020Kb
Load more
										Recommended publications
									
								- 
												  Postgraduate Research Symposium Programme 23 June 2021[Type here] School of Biomedical Engineering & Imaging Sciences Postgraduate Research Symposium Programme 23 June 2021 Organising Committe Agenda MS Teams Live Event 1 You can join Live Event 1 here. Time Speaker Title Professor Sebastien Ourselin Introduction Head of the School of Biomedical Engineering & Imaging Sciences, King's and College London Welcome 13:00 – 13:05 – 13:05 13:00 Dr Samantha Terry Senior Lecturer in Radiobiology, School of Biomedical Engineering & Imaging Sciences, King's College London Ines Costa PhD student, School of Biomedical Engineering & Imaging Sciences, King's Public Engagement College London 13:05 – 13:15 – 13:15 13:05 Aishwarya Mishra PhD student, Centre for Doctoral Training (CDT) in Smart Medical Imaging, King's College London and Imperial College London Dr Valentina Vitiello Professional Services Deputy Representative for the School DDI Committee; Diversity and Bullying Specialist Technical Operations Manager, School of Biomedical Engineering & Imaging Sciences, King's College London 13:15 – 13:25 13:25 – 13:15 Dr Stamatia Giannarou Royal Society University Research Fellow and Lecturer in Surgical Cancer Keynote Speaker Technology and Imaging at the Hamlyn Centre for Robotic Surgery, Department of Surgery and Cancer, Imperial College London Cognitive Vision in Robotic Surgery 13:25 – 14:05 – 14:05 13:25 Please refer to page 7 for further details. Student Please refer to page 4 for details. Three-Minute Thesis Presentations 14:05 – 14:35 – 14:35 14:05 Student Please refer to pages 5-6 for details. 1-Minute Poster Pitches 14:35 – 15:00 15:00 – 14:35 1 Poster Sessions The poster sessions will be taking place in two streams on the Wonder.me platform.
- 
												  Biology Powerhouse Raises Railway AlarmNEWS IN FOCUS to enrol all participants by 2018. Certain factors make researchers optimis- tic that the British study will succeed where the US one failed. One is the National Health Service, which provides care for almost all pregnant women and their children in the United Kingdom, and so offers a centralized means of recruiting, tracing and collecting medical information on study participants. In the United States, by contrast, medical care is provided by a patchwork of differ- ent providers. “I think that most researchers in the US recognize that our way of doing population-based research here is simply different from the way things can be done in the UK and in Europe, and it will almost always be more expensive here,” says Mark Klebanoff, a paediatric epidemiologist at Nationwide Children’s Hospital in Colum- bus, Ohio, who was involved in early dis- cussions about the US study. The Francis Crick Institute sits at the nexus of three central London railway hubs. At one stage, US researchers had planned to knock on doors of random houses looking URBAN SCIENCE for women to enrol before they were even pregnant. “It became obvious that that wasn’t going to be a winning formula,” says Philip Pizzo, a paediatrician at Stanford University Biology powerhouse in Palo Alto, California, who co-chaired the working group that concluded that the National Children’s Study was not feasible. raises railway alarm “The very notion that someone was going to show up on your doorstep as a representa- tive from a government-funded study and Central London’s Francis Crick Institute fears that proposed say ‘Are you thinking of getting pregnant?’ train line will disrupt delicate science experiments.
- 
												  Bloomsbury Scientists Ii Iiii Bloomsbury Scientists ii iii Bloomsbury Scientists Science and Art in the Wake of Darwin Michael Boulter iv First published in 2017 by UCL Press University College London Gower Street London WC1E 6BT Available to download free: www.ucl.ac.uk/ ucl- press Text © Michael Boulter, 2017 Images courtesy of Michael Boulter, 2017 A CIP catalogue record for this book is available from the British Library. This book is published under a Creative Commons Attribution Non-commercial Non-derivative 4.0 International license (CC BY-NC-ND 4.0). This license allows you to share, copy, distribute and transmit the work for personal and non-commercial use providing author and publisher attribution is clearly stated. Attribution should include the following information: Michael Boulter, Bloomsbury Scientists. London, UCL Press, 2017. https://doi.org/10.14324/111.9781787350045 Further details about Creative Commons licenses are available at http://creativecommons.org/licenses/ ISBN: 978- 1- 78735- 006- 9 (hbk) ISBN: 978- 1- 78735- 005- 2 (pbk) ISBN: 978- 1- 78735- 004- 5 (PDF) ISBN: 978- 1- 78735- 007- 6 (epub) ISBN: 978- 1- 78735- 008- 3 (mobi) ISBN: 978- 1- 78735- 009- 0 (html) DOI: https:// doi.org/ 10.14324/ 111.9781787350045 v In memory of W. G. Chaloner FRS, 1928– 2016, lecturer in palaeobotany at UCL, 1956– 72 vi vii Acknowledgements My old writing style was strongly controlled by the measured precision of my scientific discipline, evolutionary biology. It was a habit that I tried to break while working on this project, with its speculations and opinions, let alone dubious data. But my old practices of scientific rigour intentionally stopped personalities and feeling showing through.
- 
												  Msc ManagementProgramme Specification (Master’s Level) MSc Management This document provides a definitive record of the main features of the programme and the learning outcomes that a typical student may reasonably be expected to achieve and demonstrate if s/he takes full advantage of the learning opportunities provided. This programme specification is intended as a reference point for prospective students, current students, external examiners and academic and support staff involved in delivering the programme and enabling student development and achievement. Programme Information Programme Title Management Award(s) MSc Programme Code N1UF Awarding Institution Imperial College London Teaching Institution Imperial College London Faculty Imperial College Business School Department Imperial College Business School Mode and Period of Study 1 calendar year full-time (12 months) Cohort Entry Points Annually in September Relevant QAA Benchmark Statement(s) and/or Master’s Degrees in Business and Management other external reference points Total Credits ECTS: 90 CATS: 180 FHEQ Level Level 7 EHEA Level 2nd cycle External Accreditor(s) AMBA, EQUIS, AACSB International Specification Details Student cohorts covered by specification 2016/17 entry Person responsible for the specification Veronica Russell, Teaching & Quality Manager Date of introduction of programme October 2005 Date of programme specification/revision September 2016 Page 1 of 11 Description of Programme Contents The MSc in Management is offered over 12 months full-time. The programme content reflects the contemporary and relevant management skills necessary for managing in turbulent environments. In particular the programme will equip the participants with conceptual and practical skills, and enable them to analyse and solve challenging problems. The programme combines academic rigour and practical relevance.
- 
												  Programme Final (1).PagesBSHS Postgraduate Conference 2015 Programme !1 The British Society for the History of Science is a company limited by guarantee: registration number 562208 and charity number 258854. BSHS Executive Secretary PO Box 3401, Norwich NR7 7JF (+44) 01603516236 Email: offi[email protected] Webpage: www.bshs.org.uk © 2014, British Society for the History of Science !2 BSHS POSTGRADUATE CONFERENCE UCL Department of Science and Technology Studies 7 – 8 – 9 JANUARY 2015 The Department of Science and Technology Studies at University College London welcomes you to the BSHS Postgraduate Conference 2015! This event is an annual conference for postgraduate scholars in the history, philosophy and sociology of science, technology and medicine interested in meeting and sharing research with other postgraduate scholars. This is a great opportunity to build professional and social networks within a supportive and constructive environment. We had an outstanding response for paper submissions and postgraduate attendance, and we are looking forward to an extraordinary conference this year. Thank you for your contribution! Sincerely, BSHS Postgraduate Conference 2015 Committee Elizabeth Jones Raquel Velho Erman Sozudogru !3 " !4 Blue: Grey: Yellow: Grant Museum of Zoology UCL Roberts Building Holiday Inn Bloomsbury 21 University Street Torrington Place Coram Street London WC1E 6DE London WC1E 7JE London WC1N 1HT CONFERENCE INFORMATION Webpage: http://www.bshs.org.uk/conferences/postgraduate-conference/2015- postgraduate-conference-ucl Facebook: https://www.facebook.com/BSHS.PG.15
- 
												  Uclpartners Academic Health Science PartnershipUCLPartners academic health science partnership Professor the Lord Ajay Kakkar, Chair, UCLPartners Professor Sir David Fish, Managing Director, UCLPartners Dr Charlie Davie, Director of UCLPartners AHSN Clare Panniker, Chief Executive, Basildon and Thurrock University Hospitals NHS Foundation Trust What is UCLPartners? Six million population 23 healthcare organisations acute and 11 higher education institutes mental health trusts; community providers and research networks 20 Clinical Commissioning Groups (CCGs) Industry partnerships in research and 26 boroughs and local councils translation of innovation into health and wealth 2 Local Enterprise Partnership – key challenge • Working with the London Enterprise Panel, established by the Mayor of London • Professor Stephen Caddick, Vice Provost (Enterprise), UCL, is the only academic representative on the Panel • Key challenges of the panel: to compete with Boston and San Francisco; improve access to the NHS market to increase venture capital • How UCLPartners is contributing: working with industry to co-create technology and devices; creating long-term partnerships with industry and giving confidence to entrepreneurs, e.g. through new business models and procurement initiatives • Other areas of joint working: MedCity, Care City, London Health Commission, three London AHSNs and preparing to enable the success of the Francis Crick Institute 3 Defragmenting the pathway – an integrated journey to transform healthcare through innovation into practice Bringing together formal designations under
- 
												  London: an Innovation Hub for Health & Life Sciences ThroughLONDON: AN INNOVATION HUB FOR HEALTH & LIFE SCIENCES THROUGH THE APPLICATION OF DATA AND AI SUPPORTED BY Next page Access the market: 19 from NHS to Biopharma CONTENTS Foreword 3 The NHS adoption of AI technologies 20 This is an interactive guide, London’s key strengths 4 l Spotlight on UCLPartners 21 so click on the title to jump to any section. An Innovative Biopharma Cluster 22 An ecosystem built for growth 5 l Case study - MultiplAI 23 Access to funding 6 Government support 7 An accessible, diverse 24 l Case study - Kheiron Medical 9 and data-rich environment Diverse population and data 24 London’s life sciences clusters 10 Partner with the Health Data 25 The Knowledge Quarter 11 Research Hubs Whitechapel: Barts Life Sciences Hub 12 l Spotlight on DATA-CAN HDR 26 White City Innovation District 13 Southbank to Sutton 14 London’s resilient COVID-19 response 27 l Case study - InstaDeep 28 Talent and educational excellence 15 Existing talent 16 How can we help 29 The next generation 17 How London & Partners can support 29 l Case study - PEP Health 18 How MedCity can support 29 2 Contents page FOREWORD COVID-19 has accelerated data-driven innovation across often siloed organisations. Similarly, policy is being the globe, with artificial intelligence and data science at developed to overcome legacy systems and regulations, the forefront of addressing human disease and health. which will underpin and speed up innovations. The coronavirus pandemic has led to increased acceptance of new technologies with strong buy-in from all corners Not only can bioinformatics and use of healthcare Allen Simpson Neelam Patel data lead to better health systems and outcomes, this of the life sciences and healthcare sector determined to CEO also has the potential to create many new jobs Acting CEO keep this momentum going.
- 
												  2021 Phd Projects and Supervisory Teams Doctoral Fellowships for Clinicians2021 PhD projects and supervisory teams Doctoral Fellowships for Clinicians The role of “persistent PAMPs” in the cytokine storm and ARDS during severe COVID-19 and highly pathogenic influenza infection. Supervisory team: David Bauer (primary supervisor, Crick) and Mahdad Noursadeghi (UCL). Inflammation associated with SARS-CoV-2 infection. Supervisory team: Rupert Beale (primary supervisor, Crick) and Wendy Barclay (Imperial College London) Effect of acute myeloid leukaemia on normal haematopoiesis. Supervisory team: Dominique Bonnet (primary supervisor, Crick) and David Taussig (The Institute of Cancer Research, Royal Marsden) Investigation and modelling of multiple myeloma pathogenetic evolution. Supervisory team: Dinis Calado (primary supervisor, Crick), Richard Houlston (The Institute of Cancer Research) and Martin Kaiser (The Institute of Cancer Research, Royal Marsden) TGF-b family ligands as potential therapeutic targets in pancreatic cancer. Supervisory team: Caroline Hill (primary supervisor, Crick) and Debashis Sarker (King’s College London) Development of multisynaptic tracing technologies to target and manipulate disease- relevant neural circuits. Supervisory team: Johannes Kohl (primary supervisor, Crick), Andrew Murray (UCL) and Rickie Patani (Crick/UCL) Human Cell Atlas: single-cell transcriptomics of vitiligo. Supervisory team: Nicholas Luscombe (primary supervisor, Crick), Magnus Lynch (King’s College London) and John Ferguson (King’s College London) Structural and biochemical analysis of Salmonella effector functions and their interaction with host proteins. Supervisory team: Katrin Rittinger (primary supervisor, Crick), Teresa Thurston (Imperial College London) and Rupert Beale (Crick) Developing new viral vectors for in vivo gene therapy. Supervisory team: Sam Rodriques (primary supervisor, Crick), Matthew Walker (UCL) and Rob Brownstone (UCL) Identifying and functionally characterising non-coding drivers of renal cancer evolution.
- 
												  Commercial Partnerships Annual Review 19/201 Overview Commercial Partnerships Annual Review 19/20 Together we will beat cancer 2 Overview Our missions & values Contents CRUK’s vision is to bring forward the day when all cancers Overview are cured. Over the last 40 years, cancer survival rates in 4 CBO’s statement the UK have doubled. In the 1970s just a quarter of people 5 Highlights from the 19/20 financial year survived. Today that figure is half. In order to improve on this, we need to work with industry partners to progress Introduction the best ideas to market. This is where the Commercial Partnerships team can help. 2 What we do and why 7 Where we do it 8 Our principles for doing business 9 Our commitment to CRUK funded researchers Our Our Our 10 Our Commercial Objectives mission vision ambition Our achievements 11 - 17 Objective 1: Supporting researchers with translational activity The mission of CRUK Commercial Together we will 18 - 19 Objective 2: Encouraging entrepreneurial culture and skills in CRUK Commercial Partnerships will be beat cancer and our research community Partnerships is to the world’s leading see 3/4 of people maximise the translation cancer translation and survive by 2034 20 - 26 Objective 3: Develop industry partnerships in therapeutics of cancer research for commercialisation 27 - 29 Objective 4: Diversify and maximise opportunities beyond therapeutics patient benefit group 30 - 31 Objective 5: Invest in our people and processes, promote diversity See our objectives on See our achievements on See our impact on 32 - 35 Objective 6: Leverage and return
- 
												  Lead Bioinformatician JD (1).PdfJob Description Job Title: Lead Bioinformatician Department/Division/Faculty: Epidemiology and Biostatistics/ Public Health/Medicine Campus location: St Mary’s Job Family/Level: Professional Services, Level 5 Responsible to: HDR UK Imperial site Director Line Management responsibility Junior bioinformatician for: Key Working Relationships Non-academia, academia and industrial partners within the HDR UK (internal): site, including HDR UK Fellows; Research Computing Services team, BRC ITMAT Data Science Group, Data Science Institute. Key Working Relationships HDR UK sites (including London sites – UCL, Kings College London, (external): London School of Hygiene and Tropical Medicine and Queen Mary University of London) Contract type: Full Time and Fixed term until 31 May 2023 Purpose of the Post HDR UK Health Data Research (HDR) UK is the new national institute for data science for health, which is being established in 2018 with long term funding support from research councils, UKRI, charitable and governmental research funders. The HDR UK seeks to drive improvements in the health of patients and populations through research at regional and national scale. The triple mission of HDR UK spans discovery of disease mechanisms in science through • Precision medicine and trials to public health; • Establishing platforms and underlying infrastructure to enable research at national scale; • Developing training and capacity opportunities. To deliver this mission, the five major London universities – UCL (coordinating), Imperial College London, King’s College London, London School of Hygiene and Tropical Medicine and Queen Mary University of London – came together as a pan London Site. The terms of this partnership are set out in the Site Agreement. The six HDR UK Sites include London, Cambridge University (the Sanger and European Bioinformatics Institute), Oxford, the Midlands, Scotland and Wales/ Northern Ireland.
- 
												  Analysis of Research and Education Indicators to Support Designation of Academic Health Science Centres in EnglandCHILDREN AND FAMILIES The RAND Corporation is a nonprofit institution that helps improve policy and EDUCATION AND THE ARTS decisionmaking through research and analysis. ENERGY AND ENVIRONMENT HEALTH AND HEALTH CARE This electronic document was made available from www.rand.org as a public INFRASTRUCTURE AND service of the RAND Corporation. TRANSPORTATION INTERNATIONAL AFFAIRS LAW AND BUSINESS NATIONAL SECURITY Skip all front matter: Jump to Page 16 POPULATION AND AGING PUBLIC SAFETY SCIENCE AND TECHNOLOGY Support RAND TERRORISM AND Browse Reports & Bookstore HOMELAND SECURITY Make a charitable contribution For More Information Visit RAND at www.rand.org Explore RAND Europe View document details Limited Electronic Distribution Rights This document and trademark(s) contained herein are protected by law as indicated in a notice appearing later in this work. This electronic representation of RAND intellectual property is provided for non-commercial use only. Unauthorized posting of RAND electronic documents to a non-RAND Web site is prohibited. RAND electronic documents are protected under copyright law. Permission is required from RAND to reproduce, or reuse in another form, any of our research documents for commercial use. For information on reprint and linking permissions, please see RAND Permissions. This report is part of the RAND Corporation research report series. RAND reports present research findings and objective analysis that address the challenges facing the public and private sectors. All RAND reports undergo rigorous peer review to ensure high standards for research quality and objectivity. Errata To: Recipients of RR-318-DH, Analysis of research and education indicators to support designation of Academic Health Science Centres in England From: RAND Corporation Publications Department Date: May 2013 Re: Corrected pages (pp.
- 
												  The Francis Crick InstituteClinical Medicine 2017 Vol 17, No 2: 105–7 PROFESSIONAL ISSUES T h e F r a n c i s C r i c k I n s t i t u t e A u t h o r s : K e i t h P e t e r s A a n d J i m S m i t h B The Francis Crick Institute Laboratory, opened in 2016, is sup- is within easy reach of GlaxoSmithKine (GSK) and Astra ported by the Medical Research Council, Cancer Research UK, Zeneca’s principal research laboratories in Stevenage and the Wellcome Trust, and University College London, King’s Col- Cambridge, respectively. lege London and Imperial College London. The emphasis on But in order to justify investment on the scale required, the research training and early independence of gifted scientists new institute needed to be more than a simple translocation to ABSTRACT in a multidisciplinary environment provides unique opportuni- a new site. ties for UK medical science, including clinical and translational After discussion and negotiation, the MRC, Cancer Research research. UK (CRUK), the Wellcome Trust and University College London (UCL) created a partnership: CRUK’s London Research K E Y W O R D S : MRC , CRUK , Wellcome , Crick , UCL , King’s , Imperial Institute (LRI) would join the NIMR, with researchers from UCL contributing expertise in the physical and clinical sciences. Importantly, the Crick was not simply to be a merger The Francis Crick Institute has been referred to as the most of LRI and NIMR but a new entity with a different ethos – a significant development in UK biomedical science for a multidisciplinary institute with a substantial new investment in generation.